HI
NBIX icon

Horizon Investments’s Neurocrine Biosciences NBIX Stock Holding History

Horizon Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Buy
71,090
+43,355
+156% +$6.43M 0.13% 127
2026
Q1 		$3.65M Sell
27,735
-27,355
-50% -$3.63M 0.04% 345
2025
Q4 		$7.81M Buy
55,090
+16,474
+43% +$2.39M 0.1% 173
2025
Q3 		$5.42M Buy
38,616
+28,903
+298% +$3.92M 0.07% 224
2025
Q2 		$1.22M Buy
+9,713
New +$1.11M 0.02% 520
2024
Q4 		– Sell
-16
Closed -$1.84K – 909
2024
Q3 		$1.84K Buy
16
+6
+60% +$823 ﹤0.01% 713
2024
Q2 		$1.38K Hold
10
– – ﹤0.01% 722
2024
Q1 		$1.38K Buy
10
+6
+150% +$819 ﹤0.01% 705
2023
Q4 		$527 Buy
+4
New +$460 ﹤0.01% 728

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Horizon Investments's NBIX Position: Q2 2026 in Review

Horizon Investments increased its Neurocrine Biosciences (NBIX) stake by 156% in Q2 2026, buying an estimated $6.43M and bringing the position to 71,090 shares worth $12M. The position accounts for 0.13% of the portfolio, ranked #127.

Horizon Investments first reported a position in NBIX in Q4 2023 and has held it in 9 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Horizon Investments held 71,090 shares of Neurocrine Biosciences worth $12M as of Q2 2026.
  • Horizon Investments bought 43,355 Neurocrine Biosciences shares in Q2 2026, an estimated $6.43M.
  • Neurocrine Biosciences made up 0.13% of Horizon Investments's portfolio in Q2 2026, its #127 holding.
  • Horizon Investments first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 9 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Horizon Investments's 13F filing for Q2 2026, filed 13 Aug 2026.